Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

LEUVEN, Belgium, November 6 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update for the nine months period ended 30 September 2008.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics' clinical development programs continue to progress as anticipated. We are now working hard to prepare for the Phase III clinical program for microplasmin in eye disease following a successful End of Phase II Meeting with the FDA. The recent positive results from our Phase II trials with microplasmin have given us further confidence that this product has the potential to make a real difference in the field of eye disease. We are also developing a good working relationship with our strategic partner Roche as the clinical development of our new anti-cancer antibody TB-403 continues to progress. With our solid financial situation, I believe that ThromboGenics will deliver further important corporate milestones over the next 12 to 18 months as we continue to work to build value for our shareholders."
Financial Update

- In the first nine months of 2008, ThromboGenics achieved

revenues of EUR 30.3 million, mainly from out-licensing activities.

Operating expenses were EUR 17.0 million during this nine month period,

the majority of which were due to R&D expenses related to an increasing

number of clinical development programs.

- As of 30 September 2008, ThromboGenics had EUR 60.9 million

in cash and cash equivalents. This compares to EUR 50.6 million on 30

September 2007 and EUR 40.1 million on 31 December 2007. ThromboGenics

believes that this level of funding will allow it to complete the Phase

III program for the initial indication for microplasmin in eye disease.

- In late July, ThromboG
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Grand Rapids, MI (PRWEB) November 22, 2014 ... the opportunity to simulate the proper management of ... training and test lung devices . Grand Rapids-based, ... Lung” plans to donate two of the respiratory ... $12,000 to $15,000 each. Grand Valley and Muskegon ...
(Date:11/21/2014)... 2014 The science of light and ... with more than 200 primary students in a traveling ... University of Otago Physics Department and funded by an ... members of the university’s OSA/SPIE Student Chapter visited six ... giving children from small, rural schools hands-on lessons in ...
(Date:11/21/2014)... 20, 2014 The November 2014 issue ... an open access journal featuring the following articles:, ... to preserve photoresponsiveness in the retina , ... situ hybridization using chromogenic substrates in zebrafish , ... and protein electrophoresis , Nuclear LC3-positive puncta ...
(Date:11/21/2014)... DIEGO , Nov. 20, 2014 ... has been dosed in its Phase 1 trial ... cisplatin for the treatment of malignant pleural mesothelioma ... Group is conducting clinical trials on ADI-PEG 20, ... agents, for the treatment of several other indications, ...
Breaking Biology Technology:Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... A new,analysis of a landmark weight loss survey ... whites to use unproven dietary,supplements for weight loss. The ... NAASO, The Obesity Society, adds to the growing body,of ... the associated health risks of overweight and obesity is ...
... - New Interactive and Intuitive Tools ... Elsevier, leading publisher of scientific, technical and ... added more,development-partner-tested features on its ScienceDirect platform. ... development partners,involvement has ensured that the new ...
... Cases of Chagas, Disease ... Blood Transfusions, ANAHEIM, Calif., Oct. 20 In the ... first blood-screening test,for Chagas, disease, some 241 blood donations in ... parasite known to cause,this serious and potentially fatal parasitic infection, ...
Cached Biology Technology:New Data Reveal Ethnicity May Play Role in Weight Loss Decisions 2New Data Reveal Ethnicity May Play Role in Weight Loss Decisions 3ScienceDirect Maximizes Research Capabilities, Enhances the Research Process 2ScienceDirect Maximizes Research Capabilities, Enhances the Research Process 3Blood Donations in U.S. Testing Positive for Chagas' Disease 2Blood Donations in U.S. Testing Positive for Chagas' Disease 3Blood Donations in U.S. Testing Positive for Chagas' Disease 4
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
(Date:11/7/2014)... conjunction with the Glendale and ... the Verdugos has announced the " GLENDALE - ... to keep the Verdugo Regional Crime Lab operational after its ... existence, the Lab has processed more than 400 DNA samples, ... "Because our number one priority is the wellbeing of ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... 2012 -- It,s time to economically value the greenhouse gas-trapping ... says mining engineer and geologist Michael Hitch of the University ... mine waste rock for its CO 2 -sequestration potential, or ... be able to offset CO 2 emissions with so-named ...
... GAINESVILLE, Fla. --- The great white shark is one of ... sensationalism, yet its evolutionary history is as misunderstood as its ... relative of megatooth sharks, the white shark,s evolutionary history has ... a study appearing in print and online today in the ...
... microbial hitchhikers we all harbor, the largest dam-removal project ... era of personal genomics are among the winners of ... administered by the American Association for the Advancement of ... professional journalists for distinguished reporting for a general audience. ...
Cached Biology News:Researchers tap into CO2 storage potential of mine waste 2Researchers tap into CO2 storage potential of mine waste 3New ancient shark species gives insight into origin of great white 2New ancient shark species gives insight into origin of great white 3Winners named in 2012 AAAS Kavli Science Journalism Award Competition 2Winners named in 2012 AAAS Kavli Science Journalism Award Competition 3Winners named in 2012 AAAS Kavli Science Journalism Award Competition 4Winners named in 2012 AAAS Kavli Science Journalism Award Competition 5Winners named in 2012 AAAS Kavli Science Journalism Award Competition 6Winners named in 2012 AAAS Kavli Science Journalism Award Competition 7Winners named in 2012 AAAS Kavli Science Journalism Award Competition 8
streptavidin, Alexa Fluor® 750–allophycocyanin conjugate (Alexa Fluor® 750–allophycocyanin streptavidin) *1 mg/mL*...
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
...
Biology Products: